Flushing, characterized by redness of the skin with warming or burning on the face and neck caused by the dilation of blood vessels near the skin, is a common niacin-induced side effect.
MK-0524A is designed to be combined with Merck’s extended-release niacin, with the intent to deliver niacin in a pill with reduced flushing. MK-0524A is currently in phase III clinical trials for use as monotherapy or when administered with a statin.
“Previous outcomes studies have shown that niacin has proven efficacy in reducing cardiovascular events and favorable effects on HDL cholesterol and triglyceride levels. It has been frustrating because its use has been limited by flushing,” said Christie Ballantyne, associate chief and professor of medicine, Baylor College of Medicine.
“These data demonstrated that MK-0524 significantly decreased the incidence and intensity of the flushing that occurred in many patients taking extended-release niacin compared to that experienced by patients taking extended-release niacin plus placebo.”